{
    "clinical_study": {
        "@rank": "3032", 
        "acronym": "BRAIN", 
        "arm_group": [
            {
                "arm_group_label": "icotinib", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Whole brain irradiation", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "NO", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this\n      clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine\n      Kinase Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient\n      with EGFR-mutant non-small cell lung cancer."
        }, 
        "brief_title": "Icotinib Treat the Patient With Brain Metastasis Epidermal Growth Factor Receptor(EGFR) Mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy", 
        "condition": [
            "Brain Metastasis", 
            "Non Small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Brain Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "no available"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patient who was confirmed  stage IV NSCLC with EGFR  activating mutation and brain\n        metastases  by pathologic histology or cytology.\n\n        Patient who brain metastases was shown in MRI or CT scan. Brain metastases lesions should\n        be more than 3.The diameter among these lesions should be more than 1 centimeter.\n\n        Males or females aged \u226518 years, < 75 years. Eastern Cooperative Oncology Group(ECOG)\n        performance status 0-1. Life expectancy \u226512 weeks. The therapy of\n        surgery,chemotherapy,radiotherapy that the patients were ever received  should be more\n        than 2 weeks ago.The patient had recovered from the treatment.\n\n        Males and females  should be contraceptive during the period of the trial until  8 weeks\n        after the last administration of icotinib.\n\n        Able to comply with the required protocol and follow-up procedures, and able to receive\n        oral medications.\n\n        Written informed consent provided.\n\n        Exclusion Criteria:\n\n        Patient was received irradiation of brain. Patient with meningeal metastases were\n        confirmed by MRI or cytology test of cerebrospinal fluid.\n\n        Patient is received the treatment of Phenytoin, carbamazepine, rifampicin, phenobarbital,\n        or St. John's Wort.\n\n        Patient was received EGFR Tyrosine Kinase Inhibitor or EGFR monoclonal antibody.\n\n        Interstitial pneumonia.Pericardial effusion, pleural effusion  is uncontrolled .\n\n        Any unstable systemic disease (including active infection, uncontrolled hypertension,\n        unstable angina, congestive heart failure, myocardial infarction within the previous year,\n        serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).\n\n        Any significant ophthalmologic abnormality ,especially severe  dry eye syndrome\n        ,keratoconjunctivitis  sicca,Sjogren syndrome,severe exposure keratitis or any other\n        disorder likely to increase the risk of corneal epithelial lesions.\n\n        Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome,\n        or inability to take oral medication, or have active peptic ulcer disease.\n\n        Female subjects should not be pregnant or breast-feeding. Adequate hematological function:\n        Absolute neutrophil count (ANC) \u22651.5 x 109/L, and Platelet count \u2265100 x 109/L.\n\n        Adequate renal function:  Serum creatinine \u2264 1.5 x ULN, or \u2265 50 ml/min. Adequate liver\n        function :Total bilirubin \u00a3 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase\n        (ALT )and Aspartate Aminotransferase (AST )< 2.5 x ULN in the absence of liver metastases,\n        or < 5 x ULN in case of liver metastases.\n\n        The symptoms of increased intracranial pressure are uncontrolled after dehydration and\n        cortisone treatment.\n\n        Patient need increase irradiation dose after routine irradiation(30GY/10f/2w) Patient\n        should treat extra cranial lesions first. Patient assessed by the investigator to be\n        unable or unwilling to comply with the requirements of the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724801", 
            "org_study_id": "c-tong1201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Whole brain irradiation", 
                "description": "WBI : 30GY /10fractions/2weeks", 
                "intervention_name": "whole brain radiation(WBI)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "icotinib", 
                "description": "Icotinib 125mg tid", 
                "intervention_name": "Icotinib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "EGFR mutant", 
        "lastchanged_date": "November 7, 2012", 
        "location": {
            "contact": {
                "email": "hysd999@hotmail.com", 
                "last_name": "Yisheng Huang, Doctor", 
                "phone": "13719211288"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510080"
                }, 
                "name": "Guangdong General Hospital"
            }, 
            "investigator": {
                "last_name": "Yilong Wu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy", 
        "other_outcome": {
            "description": "adverse events(according to CTC4.0)", 
            "measure": "Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "24months"
        }, 
        "overall_contact": {
            "email": "hysd999@hotmail.com", 
            "last_name": "Yisheng Huang, doctor", 
            "phone": "13719211288"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "intracranial progression-free survival", 
            "measure": "iPFS", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724801"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "progress-free survival", 
                "measure": "progress-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "up to 16 months"
            }, 
            {
                "description": "time of controlling brain metastasis symptom", 
                "measure": "time of controlling brain metastasis symptom", 
                "safety_issue": "No", 
                "time_frame": "18months"
            }, 
            {
                "description": "Response rate of brain metastasis", 
                "measure": "Response rate of brain metastasis", 
                "safety_issue": "No", 
                "time_frame": "12months"
            }, 
            {
                "description": "Cognitive function", 
                "measure": "Cognitive function", 
                "safety_issue": "Yes", 
                "time_frame": "18months"
            }, 
            {
                "description": "overall survival(OS)", 
                "measure": "overall survival(OS)", 
                "safety_issue": "No", 
                "time_frame": "24months"
            }
        ], 
        "source": "Guangdong Association of Clinical Trials", 
        "sponsors": {
            "collaborator": {
                "agency": "Guangdong General Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Guangdong Association of Clinical Trials", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}